Dr. Gandara on How Lung-MAP Trial is Optimal for Patient Care

Video

David R. Gandara, MD, director, Thoracic Oncology Program, professor, senior advisor to director, UC Davis Comprehensive Cancer Center, treasurer, International Association for the Study of Lung Cancer (IASLC), discusses the Lung Master Protocol (Lung-MAP) Trial and how it is an example of a rational clinical design that will impact patient care. Gandara shared this insight during an interview at the 2016 IASLC Multidisciplinary Symposium on Thoracic Oncology.

David R. Gandara, MD, director, Thoracic Oncology Program, professor, senior advisor to director, UC Davis Comprehensive Cancer Center, treasurer, International Association for the Study of Lung Cancer (IASLC), discusses the Lung Master Protocol (Lung-MAP) Trial and how it is an example of a rational clinical design that will impact patient care. Gandara shared this insight during an interview at the 2016 IASLC Multidisciplinary Symposium on Thoracic Oncology.

Since some genotypes are very rare, it is difficult for pharmaceutical companies and organizarions such as the National Cancer Institute (NCI) to conduct a single assay on a group of patients in hopes of some of them testing positive for a BRAF mutation, for example. This also proves difficult for physicians and patients, Gandara adds.

A more effective strategy could involve a larger number of patients being tested for a higher number of abnormalities with drugs available to treat them. This is documented in the Lung-MAP trial, Gandara says. Here, novel agents that are associated with predictive biomarkers can be brought to patients faster in a cost-effective manner. The collaboration is made up of NCI researchers, pharmaceutical companies, and advocacy groups, such as the Friends of Cancer Research.

Most recently, 1000 patients have been enrolled on the trial. The goal of the Lung-MAP trial is to screen 1000 patients per year and researchers are on track to do that, he says.

Related Videos
Shivaani Kummar, MBBS, FACP, Margaret and Lester DeArmond Endowed Chair of Cancer Research, Professor and Division Head, Division of Hematology/Medical Oncology, Oregon Health & Science University School of Medicine; co-director, Center for Experimental Therapeutics, co-deputy director, Knight Cancer Institute
Andre Goy, MD
Wenxin (Vincent) Xu, MD,
Guenther Koehne, MD, PhD
Alessandro Villa, DDS, PhD, MPH
Joseph Mikhael, MD
Michael Richardson, MD
Minesh Mehta, MD
Ruben Olivares, MD
Phillip J. Koo, MD